Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells
- PMID: 1458554
- DOI: 10.1007/BF00695988
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells
Abstract
Exponentially growing K562 cells incubated with 1-beta-D-arabinofuranosylcytosine (ara-C) accumulate ara-C triphosphate (ara-CTP) at a higher rate and to a greater concentration after pretreatment with 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) than do cells treated with ara-C alone. Potentiation of ara-C metabolism is due in part to an indirect effect of F-ara-A triphosphate (F-ara-ATP)-mediated reduction in deoxynucleotide pools and consequent activation of deoxycytidine kinase. Because the levels of deoxynucleotide pools and the activity of deoxycytidine kinase are cell cycle-specific, we investigated the effect of cell cycle phases on the accumulation of ara-CTP and the influence of F-ara-A pretreatment on such accumulation. Exponentially growing K562 cells were fractionated into G1, S, and G2+M phase-enriched subpopulations (each enriched by > 60%) by centrifugal elutriation. The rate of ara-CTP accumulation was 22, 25, and 14 microM/h and the rate of F-ara-ATP accumulation was 38, 47, and 33 microM/h in the G1, S, and G2+M subpopulations, respectively. The rate of elimination of arabinosyl triphosphates was similar among the different phases of the cell cycle. After pretreatment with F-ara-A, the rate of ara-CTP accumulation in the G1, S, and G2+M phase-enriched subpopulations was 43, 37, and 26 microM/h, indicating a 1.7-, 1.5-, and 1.9-fold increase, respectively. These results suggest that a combination of F-ara-A and ara-C may effectively potentiate ara-CTP accumulation in all phases of the cell cycle. This observation is consistent with the results of studies on the modulation of ara-C metabolism by F-ara-A in lymphocytes and leukemia blasts obtained from patients with chronic lymphocytic leukemia and acute myelogenous leukemia, respectively.
Similar articles
-
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.Cancer Res. 1988 Jan 15;48(2):329-34. Cancer Res. 1988. PMID: 3335008
-
Interaction of arabinosyl nucleotides in K562 human leukemia cells.Biochem Pharmacol. 1989 Oct 15;38(20):3551-8. doi: 10.1016/0006-2952(89)90127-5. Biochem Pharmacol. 1989. PMID: 2479383
-
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.Clin Cancer Res. 1995 Feb;1(2):169-78. Clin Cancer Res. 1995. PMID: 9815970 Clinical Trial.
-
Biochemical modulation of arabinosylcytosine for therapy of leukemias.Leuk Lymphoma. 1993;10 Suppl:109-14. doi: 10.3109/10428199309149122. Leuk Lymphoma. 1993. PMID: 8481660 Review.
-
Cellular and clinical pharmacology of fludarabine.Clin Pharmacokinet. 2002;41(2):93-103. doi: 10.2165/00003088-200241020-00002. Clin Pharmacokinet. 2002. PMID: 11888330 Review.
Cited by
-
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966. Cancers (Basel). 2021. PMID: 33669053 Free PMC article. Review.
-
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.Leukemia. 2014 May;28(5):1001-7. doi: 10.1038/leu.2013.297. Epub 2013 Oct 22. Leukemia. 2014. PMID: 24150216 Clinical Trial.
-
Genetic factors influencing cytarabine therapy.Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. Pharmacogenomics. 2009. PMID: 19842938 Free PMC article. Review.
-
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.Carcinogenesis. 2015 Jun;36 Suppl 1(Suppl 1):S38-60. doi: 10.1093/carcin/bgv030. Carcinogenesis. 2015. PMID: 26106143 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical